Evaxion announces closing of $10.8 million public offering

Copenhagen, denmark, january 31, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced the closing of a public offering of an aggregate of 3,997,361 of its american depositary shares (“adss”) and warrants to purchase up to 50% of the adss offered at a combined public offering price of $2.71 per ads with one accompanying warrant for each two adss.
EVAX Ratings Summary
EVAX Quant Ranking